Heerlen, NL, 17 Dec 2010 07:14 CET
Royal DSM N.V., the global Life Sciences and Materials Sciences company headquartered in the Netherlands, today announces that – in accordance with applicable IFRS accounting standards – the remaining impairment of approximately €55 million for DSM Anti-Infectives will be reversed in Q4 2010. This reversal of impairment will be reported as an exceptional item in DSM’s Q4 2010 results, which will be published on 23 February 2011.
This reversal is caused by the improved business outlook for DSM Anti-Infectives related to the new strategy, in addition to own initiatives like the new 6-APA plant in China. This reversal is a non-cash item.